Drug Discovery World

FEBRUARY 19, 2024

This has been a real cause for concern for the industry, which is also facing growing competition in the investment market from big tech and AI. Throughout 2023, oncology and rare disease indications consistently dominated the pipeline for advanced therapies, and this trend is expected to continue in 2024.

Drug Development 147

Drug Development Small Molecule Drugs Therapies 147

Drug Target Review

JUNE 19, 2024

The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JANUARY 4, 2024

What distinguishes Alder Therapeutics’ approach to regenerative cell therapy development from traditional methods, and how does it aim to reduce risks in the preclinical phase? Traditional approaches to regenerative cell therapy development are defined by several challenges. For manufacturing, it’s no different.

Therapies 98

Therapies Small Molecule Production Disease 98

The Pharma Data

JUNE 22, 2023

Kite Announces Completion of Marketing Authorization Transfer for Yescarta® CAR T-cell Therapy in Japan SANTA MONICA, Calif.–(BUSINESS in December 2022 about changes to their initial 2017 partnership whereby Daiichi Sankyo obtained the Marketing Authorization for Yescarta ®. to Gilead Sciences K.K.,

Marketing 40

Marketing Therapies Small Molecule Science 40

Drug Discovery World

MARCH 12, 2024

Adoptive T-cell therapy (ACT), particularly T-cell-based transplantation, is attracting increasing attention and is advancing rapidly since the FDA approval of CAR-T therapy for the treatment of relapsed/refractory acute lymphoblastic leukaemia and B-cell malignancies.

Molecular Biology 204

Molecular Biology Small Molecule Therapies FDA Approval 204

Drug Discovery World

DECEMBER 21, 2023

In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

FDA Approval 147

FDA Approval Therapies Small Molecule Clinical Trials 147

Drug Target Review

JULY 4, 2023

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.

Small Molecule 145

Small Molecule Drugs Clinical Pharmacology Trials 145

Drug Discovery World

FEBRUARY 13, 2024

Often this can be drug approvals, exciting research into hard-to-treat indications, or even regulatory updates that enable players within the sector to utilise the latest technologies and drive therapies to market faster, ultimately benefitting patients. But is AI the answer to the industry’s development challenges?

Small Molecule 147

Small Molecule Drugs Therapies Pharmaceutical Companies 147

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. million price point per dose.

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

OCTOBER 4, 2022

Using its proprietary compound screening platform, Oligomerix discovers and develops differentiated, oral, small molecule inhibitors of tau self-association that are easy to administer and cost-effective. . Erhardt adds that despite the ever-increasing number of people with AD, there has been an erosion of market value (from $4.2

Disease 130

Disease Small Molecule Compound Screening Clinical Development 130

Advarra

JANUARY 11, 2024

The applications of mRNA-based therapies in cancer research represent one of the next groundbreaking steps toward improved cancer treatments. Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials.

Vaccine 52

Vaccine Therapies Clinical Trials Small Molecule 52

Drug Discovery World

SEPTEMBER 29, 2023

Seven companies have been highlighted in Clarivate’s ‘Companies to Watch Report’ for delivering more effective and safer medicines to market faster by leveraging artificial intelligence (AI) and machine learning (ML) technology.

Small Molecule 130

Small Molecule Drugs Therapies Disease 130

Drug Discovery World

DECEMBER 26, 2023

Otsuka Pharmaceutical and Ionis Pharmaceuticals Otsuka Pharmaceutical and RNA therapy company Ionis have entered into a licence agreement for Otsuka to acquire exclusive marketing rights to Ionis’ hereditary angioedema (HAE) drug candidate donidalorsen in Europe.

Small Molecule 130

Small Molecule Drugs Molecular Biology Bioinformatics 130

Drug Discovery World

OCTOBER 13, 2022

Sekkei Bio has made progress toward finding therapies for diabetes and pain, and has a management team with a track record of successfully bringing drugs to market. The company has built an in-silico discovery engine based on this experience, which allows them to design and develop novel drugs and excipients. .

Research 130

Research Small Molecule Vaccine Engineering 130

Drug Discovery World

MAY 1, 2024

Many of the best-selling drugs in 2023 were monoclonal antibody (mAB) therapies, including Keytruda (pembrolizumab), Humira (adalimumab), and Dupixent (dupilumab) 1. These enable researchers to better manipulate biological molecules or identify the best candidates to progress to the next stage of development.

FDA Approval 147

FDA Approval Therapies FDA Molecular Biology 147

Drug Target Review

APRIL 16, 2024

Can you explain how Radioligand Therapy (RLT) is applicable in the treatment of both chemotherapy-resistant tumours and in naïve patients who have not undergone prior cancer treatment? How does the use of peptides in radioligand therapy (RLT) compare to monoclonal antibodies (mAbs) in terms of ease of development and selectivity?

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

Drug Discovery World

APRIL 4, 2023

The FDA approved Orserdu (elacestrant) for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. They can also be sold or traded by sponsors, such as big pharma corporations.

FDA 130

FDA FDA Approval Small Molecule Therapies 130

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. We look forward to working on this new collaboration with Biohaven, a world leader in the clinical development of CGRP-targeted therapies.” TOKYO and CAMBRIDGE, England , Dec. Vlad Coric , M.D.,

Small Molecule 40

Small Molecule Licensing Licensing Clinical Trials 40

The Pharma Data

SEPTEMBER 10, 2021

– Abrocitinib is a once-daily oral JAK1 inhibitor indicated in Great Britain for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and over, who are candidates for systemic therapy-. This is the first marketing authorization globally for abrocitinib-. About CIBINQO ® (abrocitinib).

Marketing 52

Marketing Licensing Licensing Small Molecule 52

Drug Discovery World

NOVEMBER 14, 2022

Based on research into adrenergic signaling by professor Tore Bengtsson at Stockholm University, ATR-258 is a small molecule therapy that works by selectively stimulating b2-adrenergic receptors to translocate GLUT4 to the cell membrane. . Find out more: Atrogi gets go-ahead to begin Phase I study of type 2 diabetes therapy .

Small Molecule 130

Small Molecule Drugs Therapies Treatment 130

LifeSciVC

JANUARY 16, 2024

These are incredible forecasts and CAGRs, which if we assume directionally correct, rely not only on steady growth for approved therapies but also a substantial success rate of, and continued investment in, the development pipeline. Small molecule GLP1s?

Small Molecule 140

Small Molecule Trials Therapies Disease 140

Drug Discovery World

FEBRUARY 27, 2023

What advice do you have for other start-ups hoping to launch into this market? For RNA, we’ve seen its success with Covid-19 vaccines and the approval of the first-ever RNA-targeting small molecule, risdiplam, for treating spinal muscular atrophy (SMA).  It is exciting to see where the RNA market will go from here.

RNA 130

RNA Science Small Molecule Engineering 130

Alta Sciences

AUGUST 29, 2024

Listen or read Issue 33 of The Altascientist on altasciences.com , or wherever you listen to podcasts: GROWING NEEDS FOR CNS THERAPY SOLUTIONS The different parts of the nervous system, including the brain and spinal cord and the peripheral nervous system, are important drug targets for many serious diseases affecting human health.

Drug Development 52

Drug Development Small Molecule Clinical Trials Drugs 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189

Drug Discovery World

MAY 13, 2024

Key to this is the ability to rapidly determine protein structures alone and in combination with antibodies or small molecules. With that information, researchers can map sequence changes to the spike protein to assess whether there are obvious concerns with vaccine coverage or antibody therapies.

Vaccine 147

Vaccine Virus Small Molecule Disease 147

ASPET

SEPTEMBER 7, 2023

Avalglucosidase alfa has received marketing authorization in several countries for infantile-onset and/or late-onset Pompe disease. This recently approved enzyme replacement therapy (ERT) was glycoengineered to maximize CIMPR binding through high-affinity interactions with ~7 bis-M6P moieties.

Small Molecule 40

Small Molecule Therapies Disease Treatment 40

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. An example is the collaboration between Novartis and the University of Oxford to develop a gene therapy for spinal muscular atrophy, a rare genetic disease.

Drug Development 82

Drug Development Clinical Trials Drugs Therapies 82

The Pharma Data

DECEMBER 9, 2020

Liebisch , Vigil Neuroscience is developing a pipeline of precision-based therapies to combat both rare and common neurodegenerative diseases by restoring the vigilance of microglia. It will if the following five companies, which all launched this year with Series A financing, have anything to say about it. . Vigil Neuroscience.

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

Creative Biolabs

JUNE 29, 2023

At present, a large number of G protein-coupled receptor-targeted drugs have been marketed, and a large number of drugs are under development. While the development of small molecule drugs targeting GPCRs, the development of monoclonal antibody drugs has also received great attention.

Therapies 52

Therapies Small Molecule Research Drug Development 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. Addressing this need in the market has allowed us penetration to work with 75% of the top twenty pharma companies.

Science 130

Science Molecular Biology Therapies Disease 130

Drug Target Review

MARCH 1, 2024

How significant are the results in terms of advancing TCR-T cell therapy and AMP immunotherapy for the treatment of solid tumours? We have already applied this approach to several important tumour targets where enhancements in TCR-T therapy may lead to important gains in clinical benefit, including mutated KRAS, NY-ESO, and HPV E7 antigens.

Immune Response 105

Immune Response Vaccine Therapies Small Molecule 105

Drug Discovery World

APRIL 27, 2023

Megan Thomas takes a snapshot of the US biotech market and some of the ongoing research coming out of the US. Pegcetacoplan, an injectable treatment, is the first medication to use targeted C3 therapy to diffuse the harmful three- pronged “complement cascade” triggered by GA, a physiological response that attacks and destroys healthy tissue.

Small Molecule 130

Small Molecule Science Drugs FDA Approval 130

PPD

OCTOBER 18, 2023

There has been an unprecedented expansion of different types of pharmaceutical therapies, as well as a change in the overall approach to health care. Continued expansion of the biotech industry is occurring in parallel, with an estimated compound annual growth rate of 13.96% from 2023-2030.

Laboratories 52

Laboratories Assay Development Small Molecule Packaging 52

Drug Discovery World

NOVEMBER 1, 2022

Ground-breaking therapies . The company said: “As of the 28 September 2022, patients have been dosed with Auceliciclib, and dosing has completed for Cohorts 1 – 5 of the monotherapy dose escalation, and Cohorts 1a, 1b for the combination therapy arms with Temozolomide (TMZ).

Drugs 130

Drugs Science Therapies Clinical Trials 130

The Pharma Data

AUGUST 7, 2021

Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology. The acquisition of Vividion strengthens Bayer’s small molecule capabilities and expands Bayer’s reach into new modalities.

Small Molecule 52

Small Molecule Drugs Pharmaceutical Companies Therapies 52

Drug Discovery World

SEPTEMBER 26, 2022

A report by the medical charity LifeArc 1 puts the timeframe for a therapy brought to market through repurposing methods at anywhere from one to three years. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Volume 23 – Issue 4, Fall 2022. References .

Pharmaceutical Companies 130

Pharmaceutical Companies Drugs Pharmaceuticals Clinical Trials 130

Drug Target Review

JULY 18, 2024

About the author Dr Chris Haqq, Executive Vice President, Head of Research and Development and Chief Medical Officer of Elicio Therapeutics Dr Haqq is an oncologist with more than two decades of experience in drug development working across cell therapy, small molecule and biologics in large and small biotech settings.

Drug Development 59

Drug Development Clinical Trials Drugs Small Molecule 59